

To determine if the addition of weekly zinc and weekly zinc plus vitamin A to routine tuberculosis (TB) treatment improves the outcome of the treatment in Nigeria

Submission date 24/06/2009	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 24/07/2009	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 23/10/2020	Condition category Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Lovett Lawson

Contact details
Zankli Medical Centre
1021, Shehu Yaradua Way
Abuja
Nigeria
P.O.Box 7745
+234 (0)803 701 2487
lovettlawson@hotmail.com

Additional identifiers

Study information

Scientific Title

Diagnosis of tuberculosis and the role of micronutrients in the treatment of pulmonary tuberculosis (PTB) in Nigeria: a double-blinded, placebo-controlled, multicentre, supplementation clinical trial

Study objectives

To assess the efficacy of weekly zinc and weekly zinc plus vitamin A as an adjunct for the treatment of patients with tuberculosis (TB).

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Liverpool School of Tropical Medicine Research Ethics Committee approved on the 25th July 2003 (ref: 03.33)
2. Ministry of Federal Capital Territory, Health and Social Services Department, Nigeria approved on the 23rd June 2003 and 16th July 2003 (ref: MFCT/GEN/24/VOL1)

Study design

Double-blinded block randomised placebo-controlled multicentre supplementation clinical trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Tuberculosis

Interventions

Patients were randomised in blocks to receive:

1. Anti-TB routine treatment plus 90 mg elementary zinc weekly (as zinc sulphate in a lactose matrix in form of a tablet) plus a placebo that looked identical to vitamin A
2. Anti-TB treatment plus 90 mg elementary zinc weekly plus 1500 retinol (equivalent to 5000 IU of vitamin A as retinyl acetate, in a capsular form)
3. Anti-TB treatment plus weekly placebos that were similar to zinc tablets and vitamin A capsules

All capsules and tablets were prepared and sent from the Liverpool School of Tropical Medicine. The tablets and the capsules were indistinguishable to both researchers and patients.

Total duration of treatment was 8 months and the total duration of the follow-up for all arms was 6 months.

Intervention Type

Supplement

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Zinc, vitamin A supplementation

Primary outcome(s)

1. To determine the time to sputum clearance of bacilli (proportion of TB bacilli cleared from sputum at enrolment, 2nd and 6th month, using smear microscopy in the three groups)
2. To determine the resolution of lesion areas in chest x-rays in the three groups at enrolment, 2nd and 6th month

Key secondary outcome(s)

To look at the clinical and laboratory differences between the three groups at enrolment, 2nd and 6th month.

Completion date

30/06/2005

Eligibility**Key inclusion criteria**

1. Willingness to take part in the study
2. Newly diagnosed as having active PTB as per the World Health Organization (WHO) definition of smear positive TB
3. Aged 15 years and above, either sex
4. Should not have a history of anti-TB treatment

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

350

Key exclusion criteria

1. Moderate to severe surgery during the previous month
2. History of diabetes mellitus or severe cardiovascular, liver or renal disease
3. Previous treatment for TB
4. Taking corticosteroids, zinc or vitamin A supplementation during the previous month
5. Pregnant, lactating or taking oral contraceptives
6. Patient could not attend follow up visits regularly

Date of first enrolment

01/09/2003

Date of final enrolment

30/06/2005

Locations**Countries of recruitment**

Nigeria

Study participating centre

Zankli Medical Centre

Abuja

Nigeria

P.O.Box 7745

Sponsor information**Organisation**

Zankli Medical Centre (Nigeria)

ROR

<https://ror.org/02msz7b29>

Funder(s)**Funder type**

Hospital/treatment centre

Funder Name

Zankli Medical Centre (Nigeria)

Results and Publications**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/12/2010	23/10/2020	Yes	No